Health And Medicine
-
VUMC-led network to focus on polygenic risk for common diseases
With the aid of a $75 million, five-year grant renewal, the Electronic Medical Records and Genomics Network (eMERGE) will venture beyond its current focus on monogenic disease to scoring research participants relative risk for complex heritable diseases such as cardiovascular disease, chronic kidney disease and type 2 diabetes. Read MoreJul 1, 2020
-
VICTR named to key role to streamline COVID-19 research response
The Vanderbilt Institute for Clinical and Translational Research (VICTR), which provides comprehensive support for clinical and translational research at Vanderbilt University Medical Center (VUMC), has been named Administrative Coordinating Center (ACC) of a national effort to streamline the research response to life-threatening lung and heart problems caused by COVID-19. Read MoreJun 24, 2020
-
Study shows better option for treatment of inoperable anal cancer
People with inoperable anal cancer treated with carboplatin-paclitaxel had fewer complications and lived longer than those who received another chemotherapy that has been more often administered. Read MoreJun 24, 2020
-
Study finds zinc doesn’t reduce mortality, other health risks, for heavy alcohol users living with HIV/AIDS
Zinc supplementation did not reduce mortality, cardiovascular risk, levels of inflammation or microbial translocation among people with heavy alcohol use living with HIV/AIDS, according to a Vanderbilt-led study. Read MoreJun 24, 2020
-
Glaucoma drug studied to prevent lung Infection in COVID-19 patients
Vanderbilt University Medical Center is evaluating razuprotafib, a drug used to treat glaucoma, in a new randomized, investigational trial for the prevention and treatment of acute respiratory distress syndrome (ARDS) in adult patients with moderate to severe COVID-19. Read MoreJun 24, 2020
-
A connection to schizophrenia
The insula, a small region of the brain involved in diverse brain functions had widespread dysconnectivity in schizophrenia, Vanderbilt researchers found. Read MoreJun 23, 2020
-
Single mutation causes seizure disorder
A single mutation in one gene can impair inhibitory signaling in the brain and cause multiple types of seizures and behavioral abnormalities. Read MoreJun 22, 2020
-
Major U.S. trial closes showing no benefit for hydroxychloroquine in COVID-19
The Outcomes Related to COVID-19 Treated with Hydroxychloroquine among In-patients with Symptomatic Disease (ORCHID) trial stopped enrolling new patients based on the fourth scheduled interim analysis showing no evidence of benefit or harm. Read MoreJun 21, 2020
-
Probing DNA damage repair
After discovering a new mechanism for DNA damage repair last year, Vanderbilt biochemists now provide direct evidence for how it works. Read MoreJun 18, 2020
-
Studying cells in reduced dimensions
Vanderbilt cell biologists have developed an unbiased, quantitative framework for evaluating single-cell data. Read MoreJun 18, 2020
-
All of Us program launches cloud-based research platform
On May 27, the All of Us Research Program launched the beta version of its cloud-based research platform, the Researcher Workbench. Read MoreJun 18, 2020
-
Robotic technology speeds arrhythmia gene classification
Vanderbilt University Medical Center investigators have used high-throughput robotic technology to rapidly study and classify variations in a gene linked to heart rhythm disorders and cardiac conditions. Read MoreJun 12, 2020
-
C.diff captures blood cell cofactor to build defensive shield
Vanderbilt University Medical Center scientists have identified a C. diff protein system that senses and captures heme (part of hemoglobin) to build a protective shield that fends off threats from our immune system and antibiotics. Read MoreJun 10, 2020
-
Vanderbilt, AstraZeneca sign new COVID-19 antibody agreement
After evaluating the ability of more than 1,500 monoclonal antibodies to bind and neutralize the COVID-19 virus, SARS-CoV-2, in the laboratory, AstraZeneca signed an exclusive license to six candidate antibodies in Vanderbilt’s portfolio. Read MoreJun 9, 2020
-
Staph’s activation of blood clotting
Staph bacteria may change the factor they use to activate blood clotting — to evade the immune response — a new study suggests. Read MoreJun 9, 2020
-
Protecting the injured kidney
Leslie Gewin and colleagues have upended conventional dogma about Wnt/beta-catenin signaling in the kidney, finding that it protects against chronic kidney disease rather than promoting it. Read MoreJun 4, 2020
-
Potential new cancer target
Vanderbilt researchers have discovered the involvement of a certain type of adenosine receptor in mediating signaling that supports tumor growth and metastasis. Read MoreJun 4, 2020
-
Remdesivir helps reduce COVID-19 recovery time: study
The investigational antiviral drug remdesivir can shorten the time to recovery in adults hospitalized with COVID-19, according to preliminary results of a clinical trial published last month in The New England Journal of Medicine. Read MoreJun 4, 2020
-
Multinational consortium reports COVID-19 impact on cancer patients
People with cancer sickened by COVID-19 have a crude death rate of 13%, according to the largest series of data released thus far from a multinational perspective. The data on more than 900 patients also revealed cancer-specific factors associated with increased mortality. Read MoreJun 3, 2020
-
Artificial intelligence offers a chance to optimize COVID-19 treatment in international partnership
Jonathan Irish joins an international collaboration by deploying artificial intelligence to optimize COVID-19 treatment and vaccine development. Read MoreMay 29, 2020